



BETULONIC ACID DIPEPTIDE - A NON-NUCLEOSIDE ANTI-HIV AGENT

Description and properties

A new antiviral agent applicable in HIV-1 therapy has been developed in N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry in collaboration with the Institute of Chemical-Energy Technologies of Siberian Branch of RAS, Institute of Petrochemistry and Catalysis of RAS and Vektor State Scientific Center of Virology and Biotechnology. The compound is synthesized from natural triterpene betuline – available metabolite of birch bark. Anti-HIV activity of the agent is substantially higher than that of azidothymidine.



Technical-Economic Advantages

- Low-toxic inhibitor of embedding the virus into the cell
- Technologically simple. Obtained on the basis of available plant material, which provides at least fivefold decrease in the cost of the annual therapy

Application

- Anti-HIV agent
- Immunostimulant
- Antiherpetic

Patents

Patent of RF № 2211843 of 25.01.2002. “N’ -{N-[3-oxo-20(29)-lupene-28-oyl]-9-aminononanoyl}-3-amino-3-phenylpropionic acid with immunopotentiating and antiviral activity.

Practical realization

- The main part of pre-clinical testing is completed
- Pilot plant schedule is developed

*N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry,
Siberian Branch of the Russian Academy of Sciences
9, Acad. Lavrentiev Ave, 630090, Novosibirsk, 90, Russia
Prof. E.E. Shults, Head of the Laboratory
Tel.: (383) 330-85-33, E-mail: schultz@nioch.nsc.ru*